YD Bio Limited Warrants (YDESW) Financials
Newest figures come from the 10-K for FY2025, filed May 26, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the YDESW SEC filings page.
YD Bio Limited Warrants (YDESW) reported $597K in revenue for fiscal year 2025, up 16.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
YD Bio Limited Warrants does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
YD Bio Limited Warrants passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
YD Bio Limited Warrants reported a net loss of $8.3M while operations used $6.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
YD Bio Limited Warrants held $6.0M in cash against $7K in long-term debt as of Q4 2025.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
YDESW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
YDESW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q2'2510-Q | Q4'2410-K |
|---|---|---|---|
| Total Assets | $13.8M+100.7% | $0 | $6.9M |
| Current Assets | $9.7M+178.9% | N/A | $3.5M |
| Cash & Equivalents | $6.0M+91.8% | N/A | $3.1M |
| Short-Term Investments | $0 | N/A | $0 |
| Inventory | $1.9M+4934.3% | N/A | $37K |
| Accounts Receivable | $167K+93.4% | N/A | $87K |
| Long-Term Investments | $0 | N/A | $0 |
| Total Liabilities | $16.6M+5971.6% | $68K | $274K |
| Current Liabilities | $1.6M+524.8% | N/A | $263K |
| Non-Current Liabilities | $15.0M+137184.6% | N/A | $11K |
| Long-Term Debt | $7K | N/A | N/A |
| Total Equity | -$2.9M-143.3% | -$68K | $6.6M |
| Retained Earnings | -$10.2M-431.3% | -$68K | -$1.9M |
Not reported in any period shown, so not listed: Goodwill.
YDESW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
YDESW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$2.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Where YD Bio Limited Warrants Ranks
Frequently Asked Questions
What is YD Bio Limited Warrants's annual revenue?
YD Bio Limited Warrants (YDESW) reported $597K in total revenue for fiscal year 2025. This represents a 16.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is YD Bio Limited Warrants's revenue growing?
YD Bio Limited Warrants (YDESW) revenue grew by 16.9% year-over-year, from $510K to $597K in fiscal year 2025.
Is YD Bio Limited Warrants profitable?
No, YD Bio Limited Warrants (YDESW) reported a net income of -$8.3M in fiscal year 2025.
What is YD Bio Limited Warrants's EBITDA?
YD Bio Limited Warrants (YDESW) had EBITDA of -$5.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does YD Bio Limited Warrants have?
As of fiscal year 2025, YD Bio Limited Warrants (YDESW) had $6.0M in cash and equivalents against $7K in long-term debt.
What is YD Bio Limited Warrants's gross margin?
YD Bio Limited Warrants (YDESW) had a gross margin of 28.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is YD Bio Limited Warrants's free cash flow?
YD Bio Limited Warrants (YDESW) recorded an outflow of $8.0M in free cash flow during fiscal year 2025. This represents a -519.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is YD Bio Limited Warrants's operating cash flow?
YD Bio Limited Warrants (YDESW) recorded an outflow of $6.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are YD Bio Limited Warrants's total assets?
YD Bio Limited Warrants (YDESW) had $13.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are YD Bio Limited Warrants's capital expenditures?
YD Bio Limited Warrants (YDESW) invested $1.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does YD Bio Limited Warrants spend on research and development?
YD Bio Limited Warrants (YDESW) invested $1.6M in research and development during fiscal year 2025.
What is YD Bio Limited Warrants's current ratio?
YD Bio Limited Warrants (YDESW) had a current ratio of 5.88 as of fiscal year 2025, which is generally considered healthy.
What is YD Bio Limited Warrants's return on assets (ROA)?
YD Bio Limited Warrants (YDESW) had a return on assets of -60.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Why is YD Bio Limited Warrants's debt-to-equity ratio negative or not reported?
YD Bio Limited Warrants (YDESW) has negative shareholder equity of -$2.9M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is YD Bio Limited Warrants's Piotroski F-Score?
YD Bio Limited Warrants (YDESW) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are YD Bio Limited Warrants's earnings high quality?
YD Bio Limited Warrants (YDESW) reported a net loss of $8.3M while operations used $6.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.